Spero Therapeutics, Inc.
SPRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001701108
No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Spero Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 48 | 56 | +8 |
| Shares | 14.3M | 14.4M | +112.9K (+0.8%) |
| Value | $20.6M | $20.8M | +$223.6K (+1.1%) |
New holders (11)
Institutions that held Spero Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ameriprise Financial Inc | 467,960 | $678.5K | 0.00% |
| Acadian Asset Management LLC | 173,539 | $250.0K | 0.00% |
| Squarepoint Ops LLC | 78,063 | $113.2K | 0.00% |
| Prudential Financial Inc | 24,400 | $35.4K | 0.00% |
| Royce & Associates LP | 22,851 | $33.1K | 0.00% |
| Virtu Financial LLC | 22,195 | $32.0K | 0.00% |
| Mackenzie Financial Corp | 17,198 | $25.3K | 0.00% |
| Citadel Advisors LLC | 14,956 | $21.7K | 0.00% |
| Simplex Trading, LLC | 2,281 | $3.00K | 0.00% |
| Rhumbline Advisers | 458 | $664 | 0.00% |
| FMR LLC | 4 | $6 | 0.00% |
Sold out (3)
Institutions that held Spero Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Marshall Wace, LLP | 64,388 | $93.4K |
| Invesco Ltd. | 18,979 | $27.5K |
| TD Waterhouse Canada Inc. | 300 | $456 |